Tradestie Institutional Equity Comparison Engine
LYRA vs CLYM โ Head-to-Head Terminal
6-dimension institutional benchmarking across valuation, multi-year operating margins, normalized momentum, and dealer gamma corridors.
Pillar 1 Executive Scorecard & Category Winner Tally
CLYM Overall Edge
CLYM Captures Institutional Edge (2โ0 Pillars ยท 6โ1 Matrix Metrics)
Tradestie Institutional Equity Comparison Engine assigns the overall head-to-head edge to Climb Bio, Inc. Common Stock (CLYM) driven by superior Growth & Margin, Momentum & Technical. Fundamentally, LYRA trades at N/M Forward P/E with -25032.0% operating margin (-87.2% YoY revenue) versus CLYM at N/M Forward P/E and 0.0% operating margin (+0.0% YoY). In options structure, LYRA sits in UNCLASSIFIED (N/A IV; Dealer Gamma Walls on Pro) against CLYM sits in UNCLASSIFIED (N/A IV; Dealer Gamma Walls on Pro).
Valuation Winner
Tie
LYRA N/M vs CLYM N/M Fwd P/E
Growth & Margin Winner
CLYM
Op Margin -25032.0% vs 0.0% ยท YoY -87.2% vs +0.0%
Momentum & Technical Winner
CLYM
1Y -94.3% vs +407.4% ยท 52W Pos 1% vs 48%
Options & Structure Winner
Tie
UNCLASSIFIED (N/A IV) vs UNCLASSIFIED (N/A IV)
LYRA
NASDAQ
Lyra Therapeutics, Inc. Common Stock
Surgical & Medical Instruments & Apparatus
$0.49
-62.5% 1D
Market Cap
$2.3M
1M Return
-62.5%
1Y Return
-94.34%
Forward P/E
N/M
Unified AI Score
52.2 / 100
HOLD
Tech 60.0
Fund 56.0
Flow 50.0
Mom 59.0
CLYM
NASDAQ
Climb Bio, Inc. Common Stock
Pharmaceutical Preparations
$9.64
-3.02% 1D
Market Cap
$608.5M
1M Return
-0.92%
1Y Return
+407.37%
Forward P/E
N/M
Unified AI Score
45.7 / 100
HOLD
Tech 41.0
Fund 47.0
Flow 50.0
Mom 54.0
Pillar 2 Normalized Relative Return Performance (% Indexed to 0%)
1Y Indexed Return:
LYRA -94.34%
CLYM +407.37%
Spread: +362.4 pp (CLYM Lead)
Pillar 3 Operating Profitability Benchmark (Trailing 12-Month)
LYRA TTM Op. Margin: -25032.0%
CLYM TTM Op. Margin: 0.0%
Standardized multi-year USD domestic revenue schedules are unavailable for foreign-domiciled ADR filing schedules on LYRA vs CLYM. Trailing 12-month operating profitability (LYRA -25032.0% vs CLYM 0.0%) and valuation multiples (LYRA N/M vs CLYM N/M Forward P/E) are benchmarked directly in Pillar 4 below.
Pillar 4 Head-to-Head Fundamental & Valuation Matrix
| Institutional Metric | LYRA | CLYM | Criterion | Row Winner |
|---|---|---|---|---|
| Market Capitalization Scale | $2.3M | $608.5M | Larger Scale | CLYM |
| Trailing P/E Ratio Valuation | N/M | N/M | Lower Multiple | Tie |
| Forward P/E Ratio Valuation | N/M | N/M | Lower Multiple | Tie |
| Revenue Growth (YoY) Growth | -87.2% | +0.0% | Higher Growth | CLYM |
| Operating Margin (TTM) Profitability | -25032.0% | 0.0% | Higher Margin | CLYM |
| Net Profit Margin Profitability | 0.0% | 0.0% | Higher Margin | Tie |
| Return on Equity (ROE) Capital Efficiency | -404.5% | -29.3% | Higher ROE | CLYM |
| 52-Week Range Position Momentum | 1% ($0โ$38) | 48% ($2โ$18) | Stronger Trend | CLYM |
| Beta / 30D Volatility Risk Regime | 0.33ฮฒ ยท 248% Vol | 1.52ฮฒ ยท 112% Vol | Lower Realized Risk | CLYM |
| Unified Institutional Score Composite Signal | 52.2 / 100 (HOLD) | 45.7 / 100 (HOLD) | Higher Composite | LYRA |
Pillar 5 Options Structure, IV Regime & Dealer Gamma Corridor
Full LYRA vs CLYM Buy Guide
LYRA
UNCLASSIFIED
0d in phase ยท OBV NEUTRAL
Put Wall Floor
Pro Only
Call Wall Magnet
Pro Only
IV Percentile
N/A
IV Regime
Unclassified
CLYM
UNCLASSIFIED
0d in phase ยท OBV NEUTRAL
Put Wall Floor
Pro Only
Call Wall Magnet
Pro Only
IV Percentile
N/A
IV Regime
Unclassified
Pillar 6 90-Day Technical & R&D Innovation Disclosures
Corporate R&D & Foundry Tracker
Neither LYRA nor CLYM registered frontier semiconductor/AI engineering publications in the trailing 90-day window; head-to-head edge is anchored on operating margin trajectory, valuation multiples, and options structure above.